Immunosuppression with mycophenolate mofetil attenuates the development of hypertension and albuminuria in deoxycorticosterone acetate-salt hypertensive rats

被引:37
|
作者
Boesen, Erika I. [1 ]
Williams, Douglas L. [1 ]
Pollock, Jennifer S. [1 ]
Pollock, David M. [1 ]
机构
[1] Med Coll Georgia, Vasc Biol Ctr, Augusta, GA 30912 USA
基金
美国国家卫生研究院;
关键词
hypertension; kidney; macrophage; mineralocorticoid; T-lymphocyte; IMMUNE CELL INFILTRATION; ANGIOTENSIN-II; SENSITIVE HYPERTENSION; BLOOD-PRESSURE; RENAL DAMAGE; MINERALOCORTICOID RECEPTORS; ARTERIAL-PRESSURE; OXIDATIVE STRESS; T-CELL; KIDNEY;
D O I
10.1111/j.1440-1681.2010.05428.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
P>1. The interplay between the immune and renin-angiotensin systems is emerging as a crucial factor in the development and progression of hypertension. The aim of the present study was to determine the involvement of immune cells in the hypertension and renal injury produced by a non-angiotensin II-dependent form of hypertension, namely deoxycorticosterone acetate (DOCA)-salt-induced hypertension, in rats. 2. Male Sprague-Dawley rats underwent uninephrectomy and received either a sustained-release pellet of DOCA s.c. and 0.9% NaCl (saline) to drink for 21 days or a placebo pellet and water to drink for 21 days. Additional groups of DOCA-salt- and placebo-treated rats were treated concurrently with the immune suppressant mycophenolate mofetil (MMF; 30 mg/kg per day). Rats were placed in metabolic cages for 24 h urine collection prior to and at weekly intervals during the 21 day experimental period. 3. Mycophenolate mofetil significantly attenuated the development of hypertension in DOCA-salt rats compared with untreated DOCA-salt hypertensive rats (mean arterial pressure by telemetry on Day 18 146 +/- 7 vs 180 +/- 3 mmHg, respectively; P < 0.001), as well as proteinuria (87 +/- 27 vs 305 +/- 63 mg/day, respectively, on Day 21) and albuminuria (51 +/- 15 vs 247 +/- 73 mg/day, respectively, on Day 21). Creatinine clearance was better preserved in MMF-treated DOCA-salt rats compared with untreated DOCA-salt rats (0.74 +/- 0.07 vs 0.49 +/- 0.09 mL/min, respectively; P < 0.05), but was still significantly reduced compared with that in the placebo group (1.15 +/- 0.12 mL/min; P < 0.05). Finally, MMF treatment significantly attenuated the DOCA-salt-induced rise in renal cortical T-lymphocyte and macrophage infiltration (P < 0.05). 4. These data indicate that immune cells play a deleterious role in both the hypertension and renal injury associated with DOCA-salt hypertension.
引用
收藏
页码:1016 / 1022
页数:7
相关论文
共 50 条
  • [21] Enhanced Assymetrical Noradrenergic Transmission in the Olfactory Bulb of Deoxycorticosterone Acetate-Salt Hypertensive Rats
    Abramoff, Tamara
    Guil, Maria J.
    Morales, Vanina P.
    Hope, Sandra I.
    Soria, Celeste
    Bianciotti, Liliana G.
    Vatta, Marcelo S.
    NEUROCHEMICAL RESEARCH, 2013, 38 (10) : 2063 - 2071
  • [22] Endothelin enhances and inhibits adrenal catecholamine release in deoxycorticosterone acetate-salt hypertensive rats
    Lange, DL
    Haywood, JR
    Hinojosa-Laborde, C
    HYPERTENSION, 2000, 35 (01) : 385 - 390
  • [23] Effects of quinapril on expression of eNOS, ACE, and AT1 receptor in deoxycorticosterone acetate-salt hypertensive rats
    Hara, K
    Kobayashi, N
    Watanabe, S
    Tsubokou, Y
    Matsuoka, H
    AMERICAN JOURNAL OF HYPERTENSION, 2001, 14 (04) : 321 - 330
  • [24] Astaxanthin attenuates cardiovascular dysfunction associated with deoxycorticosterone acetate-salt-induced hypertension in rats
    Khodir, Suzan A.
    Sweed, Eman
    Gadallah, Marwa
    Shabaan, Anwaar
    CLINICAL AND EXPERIMENTAL HYPERTENSION, 2022, 44 (04) : 382 - 395
  • [25] Estrogen Metabolite 2-methoxyestradiol Prevents Hypertension in Deoxycorticosterone Acetate-salt Rats
    Wensu Yuan
    Yueyi Yu
    Jingjing Li
    Pavneet Singh
    Dong Li
    Yu Gui
    Xi-Long Zheng
    Cardiovascular Drugs and Therapy, 2013, 27 : 17 - 22
  • [26] Estrogen Metabolite 2-methoxyestradiol Prevents Hypertension in Deoxycorticosterone Acetate-salt Rats
    Yuan, Wensu
    Yu, Yueyi
    Li, Jingjing
    Singh, Pavneet
    Li, Dong
    Gui, Yu
    Zheng, Xi-Long
    CARDIOVASCULAR DRUGS AND THERAPY, 2013, 27 (01) : 17 - 22
  • [27] Hemodynamic effects of a selective endothelin-A receptor antagonist in deoxycorticosterone acetate-salt hypertensive rats
    Yu, M
    Gopalakrishnan, V
    McNeill, JR
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1998, 31 : S262 - S264
  • [28] SMOOTH-MUSCLE HYPERTROPHY AND ARTERIAL REMODELING IN DEOXYCORTICOSTERONE ACETATE-SALT HYPERTENSION
    ASHEN, MD
    HAMLYN, JM
    CLINICAL AND EXPERIMENTAL HYPERTENSION, 1994, 16 (03) : 261 - 282
  • [29] (-)-Epicatechin Reduces Blood Pressure and Improves Left Ventricular Function and Compliance in Deoxycorticosterone Acetate-Salt Hypertensive Rats
    Jackson, Douglas
    Connolly, Kylie
    Batacan, Romeo
    Ryan, Kimberly
    Vella, Rebecca
    Fenning, Andrew
    MOLECULES, 2018, 23 (07):
  • [30] Heme Arginate Suppresses Cardiac Lesions and Hypertrophy in Deoxycorticosterone Acetate-Salt Hypertension
    Jadhav, Ashok
    Ndisang, Joseph Fomusi
    EXPERIMENTAL BIOLOGY AND MEDICINE, 2009, 234 (07) : 764 - 778